Research presented at ASCO 2025 highlighted potential treatments for patients with newly diagnosed and relapsed or refractory ...

Adding lurbinectedin to atezolizumab as first-line maintenance improved PFS and OS in patients with ES-SCLC in the phase 3 ...

The program significantly shortens the FDA review time for a sponsor's final drug application submission from approximately 10-12 months to 1-2 months.